EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
Top Cited Papers
- 24 April 2011
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 17 (5) , 589-595
Abstract
Treatment options for hepatitis C virus (HCV) infection have limited efficacy and high toxicity, resulting in poor adherence and, thus, viral resistance. Identifying previously unrecognized pathways involved in HCV infection may aid the development of new therapeutics. Using an RNAi screen, Lupberger et al. have identified cellular kinases involved in HCV infection of liver cells and have tested the ability of approved inhibitors to block viral entry both in vitro and in vivo. Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies. Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors. Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry. Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo. The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81–claudin-1 co-receptor associations and viral glycoprotein–dependent membrane fusion. These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity. Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection.Keywords
This publication has 55 references indexed in Scilit:
- Monoclonal Anti-Claudin 1 Antibodies Prevent Hepatitis C Virus Infection of Primary Human HepatocytesGastroenterology, 2010
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNature Chemical Biology, 2010
- EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with AktCancer Cell, 2009
- Human occludin is a hepatitis C virus entry factor required for infection of mouse cellsNature, 2009
- Treatment failure in hepatitis C: Mechanisms of non-responseJournal of Hepatology, 2008
- Modeling oncogene addiction using RNA interferenceProceedings of the National Academy of Sciences, 2008
- Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis CProceedings of the National Academy of Sciences, 2007
- Claudin-1 is a hepatitis C virus co-receptor required for a late step in entryNature, 2007
- Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimerasProceedings of the National Academy of Sciences, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005